Therapeutic Cancer Treatments

• US 20100297118A1
• Filed: 04/16/2010
• Published: 11/25/2010
• Est. Priority Date: 12/27/2007
• Status: Abandoned Application

• Current Assignee: Infinity Pharmaceuticals, Inc.
• Original Assignee: Infinity Pharmaceuticals, Inc.
• Inventors: MacDougall, John, West, Kip A.
• Application Number:
  US12/762,008
• Publication Number:
  US 20100297118A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 491/048 the oxygen-containing ring being five-membered

Abstract

Provided are methods for treating non-small cell lung cancer by administering a therapeutically effective amount of a hedgehog inhibitor.

Claims

1. A method of treating non-small cell lung cancer comprising administering to a patient in need thereof a therapeutically effective amount of an EGFR-tyrosine kinase inhibitor and a therapeutically effective amount of a compound of formula I:

2. The method according to claim 1, wherein the therapeutically acceptable salt of the compound of formula I is a hydrochloride salt.

3. The method according to claim 1, wherein the EGFR-tyrosine kinase inhibitor is a small molecule EGFR-tyrosine kinase inhibitor.

4. The method according to claim 3, wherein the small molecule EGFR-tyrosine kinase inhibitor is selected from erlotinib, gefitinib, icotinib, lapatinib, neratinib, vandetanib, BIBW 2992 and XL-647.

5. The method according to claim 4, wherein the small molecule EGFR-tyrosine kinase inhibitor is gefitinib.

6. The method according to claim 1, wherein the EGFR-tyrosine kinase inhibitor is a monoclonal antibody.

7. The method according to claim 1, wherein the monoclonal antibody is selected from cetuximab, panitumumab, zalutumumab, nimotuzumab, necitumumab and matuzumab.

8. The method according to claim 1, wherein the compound of formula I and the EGFR-tyrosine kinase inhibitor are administered concurrently.

9. The method according to claim 1, wherein the compound of formula I and the EGFR-tyrosine kinase inhibitor are administered sequentially.

10. The method according to claim 9, wherein the compound of formula I is administered after administration of the EGFR-tyrosine kinase inhibitor.

11. The method according to claim 10, wherein the compound of formula I is administered to after administration of the EGFR-tyrosine kinase inhibitor has ceased.

12. The method according to claim 1, wherein the non-small cell lung cancer is harboring one or more EGFR mutations.

13. A method of extending relapse free survival in a non-small cell lung cancer patient comprising administering a therapeutically effective amount a compound of formula I:

14. The method according to claim 13, wherein the therapeutically acceptable salt of the compound of formula I is a hydrochloride salt.

15. The method according to claim 13, wherein the method comprises administering the compound to the patient, wherein the patient is undergoing cancer therapy.

16. The method according to claim 15, wherein the cancer therapy is treatment with an EGFR-tyrosine kinase inhibitor.

17. The method according to claim 16, wherein the EGFR-tyrosine kinase inhibitor is a small molecule EGFR-tyrosine kinase inhibitor.

18. The method according to claim 17, wherein the small molecule EGFR-tyrosine kinase inhibitor is selected from erlotinib, gefitinib, icotinib, lapatinib, neratinib, vandetanib, BIBW 2992 and XL-647.

19. The method according to claim 18, wherein the small molecule EGFR-tyrosine kinase inhibitor is gefitinib.

20. The method according to claim 16, wherein the EGFR-tyrosine kinase inhibitor is a monoclonal antibody.

21. The method according to claim 20, wherein the monoclonal antibody is selected from cetuximab, panitumumab, zalutumumab, nimotuzumab, necitumumab and matuzumab.

22. The method according to claim 15, wherein the compound of formula I and the cancer therapy are administered concurrently.

23. The method according to claim 15, wherein the compound of formula I and the cancer therapy are administered sequentially.

24. The method according to claim 23, wherein the compound of formula I is administered after the cancer therapy.

25. The method according to claim 24, wherein the compound of formula I is administered to the patient after the cancer therapy has ceased.

26. The method according to claim 15, wherein the non-small cell lung cancer is harboring one or more EGFR mutations.

27. The method according to claim 15, wherein elevated hedgehog ligand has been detected in the patient prior to administration of the compound of formula I or pharmaceutically acceptable salt thereof.

28. The method according to claim 13, wherein the method comprises administering the compound to the patient, wherein the patient has undergone cancer therapy.

29. The method according to claim 28, wherein the cancer therapy is treatment with an EGFR-tyrosine kinase inhibitor.

30. The method according to claim 29, wherein the EGFR-tyrosine kinase inhibitor is a small molecule EGFR-tyrosine kinase inhibitor.

31. The method according to claim 30, wherein the small molecule EGFR-tyrosine kinase inhibitor is selected from erlotinib, gefitinib, icotinib, lapatinib, neratinib, vandetanib, BIBW 2992 and XL-647.

32. The method according to claim 31, wherein the small molecule EGFR-tyrosine kinase inhibitor is gefitinib.

33. The method according to claim 29, wherein the EGFR-tyrosine kinase inhibitor is a monoclonal antibody.

34. The method according to claim 33, wherein the monoclonal antibody is selected from cetuximab, panitumumab, zalutumumab, nimotuzumab, necitumumab and matuzumab.

35. The method according to claim 28, wherein the non-small cell lung cancer is harboring one or more EGFR mutations.

36. The method according to claim 28, wherein elevated hedgehog ligand has been detected in the patient prior to administration of the compound of formula I or pharmaceutically acceptable salt thereof.